United States District Court, S.D. Illinois
IN RE PRADAXA (DABIGATRAN ETEXILATE) PRODUCTS LIABILITY LITIGATION. MDL No. 2385
Boehringer Ingelheim Pharmaceuticals, Inc., No. 3:15-px-230-DRH-SCW This Document Relates to Doris Henderson
DAVID R. HERNDON, District Judge.
This matter is before the Court on the plaintiff's motion for voluntary dismissal (Doc. 6) and Boehringer Ingelheim Pharmaceuticals Inc.'s ("BIPI") response thereto and cross motion to show cause why the above captioned case should not be dismissed with prejudice for failure to comply with Case Management Order Number 78 ("CMO 78") (MDL 2385 Doc. 519) (Doc. 7).
For the reasons described herein the plaintiff's motion to dismiss is DENIED. FURTHER, the Court finds plaintiff has failed to show good cause for failure to comply with the requirements of CMO 78. Accordingly, the matter is DISMISSED WITH PREJUDICE.
A. CMO 78
On May 29, 2014, the Court entered CMO 78. The provisions in CMO 78 are the result of an extensive mediation between the Pradaxa MDL Plaintiffs' Leadership Counsel and the Boehringer Defendants. The negotiations, supervised by the Special Master and this Court, were vigorous, at arm's length, and in good faith.
CMO 78 applies to all plaintiffs (1) with personal injury claims pending in this MDL at the time CMO 78 was entered and (2) who did not opt-in to the voluntary settlement program (by opt-in deadline of July 9, 2014), as well as (3) all plaintiffs with personal injury claims later filed in, removed to, or transferred to this MDL after the entry of CMO 78.
Pursuant to Section I.A. of CMO 78, plaintiffs are required to send a written notice to pharmacies and healthcare providers requesting preservation of records. CMO 78 also requires service of a signed certification verifying that all notices were sent as required. Sections II.A.- C. of CMO 78 require plaintiffs to produce a number of documents and things. Finally, Sections II.D. and E. of CMO 78 require that plaintiffs produce certain expert reports no later than thirty (30) days after the Opt-In Deadline, or by September 11, 2014.
Pursuant to CMO 78, defendants notify plaintiffs who are not in compliance with the above listed requirements. After receiving such notice, plaintiffs are given a certain amount of time to cure the identified CMO 78 deficiencies ("Cure Period"). The Cure Period is the only extension permitted under CMO 78. If the subject plaintiff fails to cure the identified deficiencies during the Cure Period, defendants "may file a Motion to Show Cause why the case should not be dismissed with prejudice." (Doc. 519 §§ I.D., II.G.). Upon the filing of such a motion, the plaintiff has "twenty (20) days to respond to the Motion and show good cause why the case should not be dismissed" (Doc. 519 §§ I.D., II.G.). "Any failure to respond to the Motion within the specified period shall lead to dismissal of the case with prejudice." (Doc. 519 §§ I.D., II.G.).
B. The Above Captioned Case
The above captioned case was filed directly into MDL 2385 (in accord with CMO 7) on March 3, 2015. Due to errors in the filing, the Clerk's office struck the plaintiff's complaint and the plaintiff filed an amended complaint on March 4, 2015. BIPI filed its answer on March 5, 2015. Since plaintiff filed this action in the MDL after the entry of CMO 78, plaintiff is required to satisfy the requirements of CMO 78.
In accordance with CMO 78, counsel for BIPI sent plaintiff a CMO 78 Notice letter (with a copy of CMO 78 enclosed) on March 5, 2015. Accordingly, plaintiff had CMO 78 deadlines on March 15, March 20, March 25, and April 5. Plaintiff did not comply with any of the March deadlines. Instead, on April 2, 2015, plaintiff filed a motion for voluntary dismissal without prejudice. While plaintiff's motion for voluntary dismissal was pending she failed to comply with the April 5 deadline and did not timely cure any CMO 78 deficiencies.
BIPI objected to the voluntary motion to dismiss and filed this cross motion to show cause in accord with CMO 78. BIPI contends the plaintiff's motion should be denied because her claims are subject to dismissal with ...